EP Patent

EP3795152A1 — Treatment of b-cell malignancies by a combination jak and pi3k inhibitor

Assigned to Incyte Holdings Corp · Expires 2021-03-24 · 5y expired

What this patent protects

This invention relates to methods of treating B-cell malignancies using a combination of inhibitors of JAK1 and/or JAK2 and inhibitors of PI3Kδ.

USPTO Abstract

This invention relates to methods of treating B-cell malignancies using a combination of inhibitors of JAK1 and/or JAK2 and inhibitors of PI3Kδ.

Drugs covered by this patent

Patent Metadata

Patent number
EP3795152A1
Jurisdiction
EP
Classification
—
Expires
2021-03-24
Drug substance claim
No
Drug product claim
No
Assignee
Incyte Holdings Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.